Bio-Rad Announces the Availability of Biogazelle’s qbase PLUS Data-Analysis Software with Bio-Rad’s CFX96 and CFX384 Real-Time PCR Systems
News Oct 07, 2009
Bio-Rad Laboratories, Inc. a multinational manufacturer and distributor of life science research and clinical diagnostic products, today announced the availability of Biogazelle’s qbasePLUS, qPCR data-analysis software for Bio-Rad’s CFX96™ and CFX384™ real-time PCR detection systems.
“The combination of qbasePLUS software with Bio-Rad’s CFX96 and CFX384 real-time PCR systems provides our customers with improved accuracy in their qPCR experiments and speeds up data analysis,” said Richard Kurtz, Marketing Manager, Amplification, Bio Rad Laboratories.
qbasePLUS is said to provide researchers with accurate gene expression analysis of their real-time PCR data by using proven solutions for data quality control, including the elimination of erroneous data, normalization for removing sample-specific non-biologic variation, and inter-run calibration, which can remove the technical variation between samples analyzed in different runs. Enhancing the reliability of the qPCR data, qbasePLUS conforms to the emerging qPCR best practices standard: Minimum Information for Publication of Quantitative Real-Time PCR Experiments (MIQE), which defines the minimum information required for the evaluation of qPCR results.
Innovative Chromatography Technologies to be Discussed at Preconference WorkshopNews
Biopharmaceutical researchers from around the globe will discuss innovative chromatographic approaches and technologies for purifying diverse biomolecules during a preconference workshop sponsored by Bio-Rad Laboratories, Inc.READ MORE
First Ever Online Event Focused on Cannabis ScienceNews
Analytical Cannabis is pleased to announce that the final line-up of speakers for the first ever cannabis science online event, The Science of Cannabis 2017 has been confirmed.READ MORE
Synpromics Announces Gene Therapy Research Partnership with Solid BiosciencesNews
Synpromics partner with Solid Biosciences ro develop treatment options Duchenne muscular dystrophy.READ MORE